Blueprint Medicines Corporation (BPMC)

Blueprint Medicines Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Operating Activities

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-155.73	-67.09	-506.98	-557.52	-644.09	313.88
Depreciation & Amortization	15.94	16.29	11.67	11.74	6.48	6.56
Asset Writedown & Restructuring Costs	-	-	-	-	259.96	-
Loss (Gain) From Sale of Investments	-70.64	-22.47	-17.47	-0.98	1.36	0.47
Stock-Based Compensation	113.74	108.91	92.67	98.97	91.63	75.53
Other Operating Activities	10.97	-163.55	24.39	-0.72	9.69	6.22
Change in Accounts Receivable	-16.76	-32.7	-7.65	-2.23	-11.81	-1.85
Change in Inventory	-6.54	-4.03	-4.37	-8.92	-12.56	-6.71
Change in Accounts Payable	-4.16	2.2	1.88	-5.82	4.22	-0.79
Change in Unearned Revenue	-8.07	-0.41	-12.69	-4.81	-4.58	-4.92
Change in Other Net Operating Assets	-24.31	-29.75	-18.3	-31.99	1.05	-1.35
Operating Cash Flow	-145.55	-192.59	-436.85	-502.28	-298.65	387.04
Operating Cash Flow Growth	-	-	-	-	-	-

Investing Activities

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Capital Expenditures	-5.36	-4.63	-16.06	-8.92	-3.09	-3.16
Investment in Securities	-54.2	-42.87	290.1	-140.33	35.38	-431.09
Other Investing Activities	-	-	-	-0.29	-258.15	-
Investing Cash Flow	-59.55	-47.5	274.04	-149.54	-225.86	-434.25

Financing Activities

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Long-Term Debt Issued	-	146.97	97.93	137.79	-	-
Long-Term Debt Repaid	-	-0.54	-0.04	-	-	-
Net Debt Issued (Repaid)	142.7	146.43	97.89	137.79	-	-
Issuance of Common Stock	72.65	126.68	21.34	8.2	50.72	617.76
Other Financing Activities	-	-	-	415.83	-	-
Financing Cash Flow	215.34	273.11	119.23	561.81	50.72	617.76

Net Cash Flow

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Foreign Exchange Rate Adjustments	-0.1	-0.91	0.2	-0.21	-0.89	-0.35
Net Cash Flow	10.13	32.12	-43.38	-90.22	-474.69	570.2

Free Cash Flow

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Free Cash Flow	-150.91	-197.22	-452.91	-511.2	-301.74	383.88
Free Cash Flow Growth	-	-	-	-	-	-
Free Cash Flow Margin	-26.85%	-38.76%	-181.61%	-250.54%	-167.56%	48.36%
Free Cash Flow Per Share	-2.38	-3.14	-7.48	-8.57	-5.16	6.83
Levered Free Cash Flow	-20.78	-76.03	-249	-273.16	-308.41	272.4
Unlevered Free Cash Flow	23.93	-33.03	-216.75	-262.06	-308.41	272.4

Additional Metrics

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash Interest Paid	87.04	79.85	38.47	9.81	-	-
Cash Income Tax Paid	1.29	1.1	-0.05	6.51	0.69	0.78

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jan 1, 2000

Data Sources Report a data error